Will Drug Prices Actually Fall?
The Inflation Reduction Act promises to reduce drug prices. But the law is more financial gamesmanship than true patient advocacy, ...
I joined an abortion clinic protest
We spoke with protesters outside of an abortion clinic to understand their position on abortion and their purpose for protesting. ...
A Pox On All Vaccines
Misinformation is a mistake of our own making. It leads to vaccine hesitancy and mistrust among patients. It also exposes ...
DOJ’s Abortion Activism
The DOJ has been actively supporting abortion access. This may appear good, but it becomes concerning when we define medical ...
Healthcare’s False Starts
Healthcare seems to repeat many mistakes lately. Beneath the rhetoric lives an uncomfortable truth. These mistakes are not a problem, ...
End of Evidence-Based Medicine
Recent findings have challenged our understanding of depression and dementia. They should also raise questions about our reliance on evidence-based ...
Amazon’s Clinical Tell
Amazon acquired One Medical, a chain of concierge primary care clinics. The move expands Amazon's presence in virtual primary care. ...
A Model to Define Probable Cause
We present a model to discern probable cause out of clinical data. We seek collaboration opportunities with interested health insurers ...
Why We Love Committees
In healthcare, we have a committee for everything. It is how we meet and how we decide. But it also ...
When Law Targets Physicians
When charges are hurled against a physician, all of medicine feels the effects. It cultivates a culture of fear that ...
Prescriptions Cause Inflation?
Many point to rising drug costs as one cause of inflation. But drug costs do not affect consumer pricing, as ...
Confronting COVID Senioritis
COVID fatigue is undeniable and most long to just move on. Instead, we should find a balance between the benefits ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
Drug Pricing Transparency in an Era of Political Polarization: What MedPricer’s Data Reveals About a Contested Policy Landscape
-
Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.
-
The Importance of Access Control in the Workplace
-
State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete
-
Chronic Care Toolbox
